Wall Street analysts expect ResMed Inc. (NYSE:RMD) to report sales of $577.00 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for ResMed’s earnings, with the lowest sales estimate coming in at $571.00 million and the highest estimate coming in at $583.00 million. ResMed reported sales of $530.40 million during the same quarter last year, which indicates a positive year-over-year growth rate of 8.8%. The business is expected to report its next quarterly earnings report on Monday, January 22nd.

On average, analysts expect that ResMed will report full year sales of $577.00 million for the current fiscal year, with estimates ranging from $2.24 billion to $2.34 billion. For the next fiscal year, analysts forecast that the business will report sales of $2.46 billion per share, with estimates ranging from $2.38 billion to $2.57 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover ResMed.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The company had revenue of $523.66 million for the quarter, compared to analysts’ expectations of $506.08 million. During the same period in the previous year, the firm posted $0.62 earnings per share. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis.

RMD has been the topic of a number of research reports. Zacks Investment Research raised shares of ResMed from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a research note on Thursday, July 6th. BidaskClub downgraded shares of ResMed from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Bank of America Corporation downgraded shares of ResMed from a “buy” rating to a “neutral” rating in a report on Wednesday, August 2nd. Credit Suisse Group downgraded shares of ResMed from an “outperform” rating to a “neutral” rating in a report on Wednesday, August 2nd. Finally, Citigroup Inc. upgraded shares of ResMed from a “neutral” rating to a “buy” rating in a report on Wednesday, August 2nd. Four investment analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $67.57.

In related news, Director Richard Sulpizio sold 24,390 shares of the stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $73.85, for a total transaction of $1,801,201.50. Following the completion of the transaction, the director now owns 28,819 shares of the company’s stock, valued at approximately $2,128,283.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brett Sandercock sold 1,250 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $77.56, for a total transaction of $96,950.00. Following the transaction, the chief financial officer now directly owns 65,941 shares of the company’s stock, valued at approximately $5,114,383.96. The disclosure for this sale can be found here. Insiders have sold a total of 99,618 shares of company stock valued at $7,553,475 in the last 90 days. Insiders own 1.77% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. West Coast Financial LLC boosted its position in shares of ResMed by 2.5% during the 3rd quarter. West Coast Financial LLC now owns 80,563 shares of the medical equipment provider’s stock worth $6,200,000 after purchasing an additional 1,932 shares during the period. State of Wisconsin Investment Board boosted its position in shares of ResMed by 6.5% during the 3rd quarter. State of Wisconsin Investment Board now owns 129,803 shares of the medical equipment provider’s stock worth $9,990,000 after purchasing an additional 7,874 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of ResMed by 18.5% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 22,032 shares of the medical equipment provider’s stock worth $1,696,000 after purchasing an additional 3,432 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of ResMed by 1.5% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 224,900 shares of the medical equipment provider’s stock worth $17,308,000 after purchasing an additional 3,330 shares during the period. Finally, Andra AP fonden boosted its position in shares of ResMed by 46.6% during the 3rd quarter. Andra AP fonden now owns 41,200 shares of the medical equipment provider’s stock worth $3,171,000 after purchasing an additional 13,100 shares during the period. 59.66% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “ResMed Inc. (RMD) Expected to Post Quarterly Sales of $577.00 Million” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/resmed-inc-rmd-expected-to-post-quarterly-sales-of-577-00-million.html.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be issued a dividend of $0.35 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.66%. ResMed’s dividend payout ratio is currently 56.68%.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Get a free copy of the Zacks research report on ResMed (RMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.